Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds.
Apoptosis
Biological Products
/ pharmacology
Cell Cycle
Cell Cycle Proteins
/ antagonists & inhibitors
Cell Proliferation
High-Throughput Screening Assays
/ methods
Humans
Leukemia, T-Cell
/ drug therapy
Molecular Docking Simulation
Protein Binding
Protein Kinase Inhibitors
/ chemistry
Protein Serine-Threonine Kinases
/ antagonists & inhibitors
Proto-Oncogene Proteins
/ antagonists & inhibitors
Tumor Cells, Cultured
Polo-Like Kinase 1
Apoptosis
Cell cycle
Drug screening
Neoplasms
Targeted chemotherapy, PLK
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
08
01
2019
accepted:
25
02
2019
pubmed:
17
3
2019
medline:
24
10
2020
entrez:
17
3
2019
Statut:
ppublish
Résumé
PLK1 has an important role in the regulation of cell cycle and represents an important target for cancer treatment. This enzyme belongs to the Polo-like kinases family, which is characterized by a regulatory domain named Polo-box domain (PBD). Rather than regular kinase inhibitors, this domain provides high selectivity to PLK1. Here, we report on four novel PLK1 PBD inhibitors identified by cytotoxicity screening and fluorescence polarization assay of a chemical library of natural and semisynthetic compounds. These compounds revealed two- to three-fold higher selectivity to the PDB of PLK1 than to those of the related family members, PLK2 and PLK3. These four substances inhibited tumor cell growth of sensitive CCRF-CEM and multidrug-resistant CEM/ADR5000 leukemia cells. The tested compounds increased the apoptotic cell fraction, which indicates apoptosis as a major mechanism of cell death. Cell cycle analysis showed compound (5) arrested the cell cycle of CCRF-CEM cells in the G2/M phase, while the other three molecules ((compound (3), compound (4), and compound (6)) exerted pronounced cytotoxicity with an increase of cells in the sub-G1 population. Molecular docking was performed for the understanding of ligand-protein interaction, the tested candidates showed strong binding affinity to PLK1 PBD. In conclusion, we identified four new chemical scaffolds that may serve as lead compounds for the development of selective PLK1 inhibitors in the future.
Identifiants
pubmed: 30877426
doi: 10.1007/s10637-019-00752-0
pii: 10.1007/s10637-019-00752-0
doi:
Substances chimiques
Biological Products
0
Cell Cycle Proteins
0
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-9Références
Van Vugt MATM, Medema RH (2005) Getting in and out of mitosis with polo-like kinase-1. Oncogene 24:2844–2859
pubmed: 15838519
Moshe Y, Boulaire J, Pagano M, Hershko A (2004) Role of polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci U S A 101:7937–7942
pubmed: 15148369
pmcid: 419535
Lowery DM, Lim D, Yaffe MB (2005) Structure and function of polo-like kinases. Oncogene 24:248–259
pubmed: 15640840
Seki A, Coppinger J a, Jang C-Y et al (2008) Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 320:1655–1658
pubmed: 18566290
pmcid: 2834883
Ohkura H, Hagan IM, Glover DM (1995) The conserved Schizosaccharomyces pombe kinase plol , required to form a bipolar. Genes Dev:1059–1073
Lane HA, Nigg EA (1996) Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135:1701–1713
pubmed: 8991084
Nigg EA (1998) Polo-like kinases: positive regulators of cell division from start to finish. Curr Opin Cell Biol 10:776–783
pubmed: 9914175
Sanhaji M, Ritter A, Belsham HR et al (2014) Polo-like kinase 1 regulates the stability of the mitotic centromere-associated kinesin in mitosis. Oncotarget 5:3130–3144
pubmed: 24931513
pmcid: 4102797
Weichert W, Ullrich A, Schmidt M et al (2006) Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci 97:271–276
pubmed: 16630118
Li H, Wang H, Sun Z et al (2017) The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis. Biosci Rep 37:BSR20170852
pubmed: 28724602
pmcid: 5554781
Schöffski P (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14:559–570
pubmed: 19474163
Berg A, Berg T (2016) Inhibitors of the polo-box domain of polo-like kinase 1. Chem Bio Chem 17:650–656
pubmed: 26662918
Rudolph D, Steegmaier M, Hoffmann M et al (2009) BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15:3094–3102
pubmed: 19383823
Raab M, Pachl F, Kramer A et al (2014) Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells. Cell Res 24:1141–1145
pubmed: 24980956
pmcid: 4152744
Liu X (2015) Targeting polo-like kinases: a promising therapeutic approach for Cancer treatment. Transl Oncol 8:185–195
pubmed: 26055176
pmcid: 4486469
García-Alvarez B, de Cárcer G, Ibañez S et al (2007) Molecular and structural basis of polo-like kinase 1 substrate recognition: implications in centrosomal localization. Proc Natl Acad Sci U S A 104:3107–3112
pubmed: 17307877
pmcid: 1805623
Liu F, Park JE, Qian WJ et al (2012) Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. ACS Chem Biol 7:805–810
pubmed: 22292814
pmcid: 3355227
Elia AEH, Rellos P, Haire LF et al (2003) The molecular basis for phosphodependent substrate targeting and regulation of Plks by the polo-box domain. Cell 115:83–95
pubmed: 14532005
Mann J (2002) Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2:143–148
pubmed: 12635177
Johnson IS, Armstrong JG, Gorman M, Burnett JP (1963) The Vinca alkaloids: a new class of oncolytic agents. Cancer Res 23:1390–1427
pubmed: 14070392
Demain AL, Vaishnav P (2011) Natural products for cancer chemotherapy. Microb Biotechnol 4:687–699
pubmed: 21375717
pmcid: 3815406
Yin Z, Song Y, Rehse PH (2013) Thymoquinone blocks pSer/pThr recognition by plk1 polo-box domain as a phosohate mimic. ACS Chem Biol 8:303–308
pubmed: 23135290
Zhang G, Zhang Z, Liu Z (2013) Scytonemin inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in multiple myeloma cells. Tumor Biol 34:2241–2247
Hamdoun S, Fleischer E, Klinger A, Efferth T (2017) Lawsone derivatives target the Wnt/β-catenin signaling pathway in multidrug-resistant acute lymphoblastic leukemia cells. Biochem Pharmacol 146:63–73
pubmed: 29061340
Saeed M, Kuete V, Kadioglu O et al (2014) Cytotoxicity of the bisphenolic honokiol from Magnolia officinalis against multiple drug-resistant tumor cells as determined by pharmacogenomics and molecular docking. Phytomedicine 21:1525–1533
pubmed: 25442261
Kuete V, Mbaveng AT, Sandjo LP et al (2017) Cytotoxicity and mode of action of a naturally occurring naphthoquinone, 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone towards multi-factorial drug-resistant cancer cells. Phytomedicine 33:62–68
pubmed: 28887921
Reindl W, Yuan J, Krämer A et al (2008) Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 15:459–466
pubmed: 18482698
Reindl W, Strebhardt K, Berg T (2008) A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem 383:205–209
pubmed: 18793607
Reindl W, Gräber M, Strebhardt K, Berg T (2009) Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3. Anal Biochem 395:189–194
pubmed: 19716361
Sakkiah S, Senese S, Yang Q et al (2014) Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors. PLoS One 9:1–9
Scharow A, Raab M, Saxena K et al (2015) Optimized Plk1 PBD inhibitors based on Poloxin induce mitotic arrest and apoptosis in tumor cells. ACS Chem Biol 10:2570–2579
pubmed: 26279064
Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547–566
pubmed: 19568282
Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9:643–660
pubmed: 20671765
Strebhardt K, Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6:321–330
pubmed: 16557283
Liu X, Lei M, Erikson RL (2006) Normal cells , but not Cancer cells , survive severe Plk1 depletion. Mol Cell Biol 26:2093–2108
pubmed: 16507989
pmcid: 1430287
Lei M, Erikson RL (2008) Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint. Oncogene 27:3935–3943
pubmed: 18297112
Yuan J, Sanhaji M, Krmer A et al (2011) Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol 179:2091–2099
pubmed: 21839059
pmcid: 3181368
Qin T, Chen F, Zhuo X et al (2016) Discovery of novel polo-like kinase 1 polo-box domain inhibitors to induce mitotic arrest in tumor cells. J Med Chem 59:7089–7096
pubmed: 27425654
Shan HM, Shi Y, Quan J (2015) Identification of green tea Catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. ChemMedChem 10:158–163
pubmed: 25196850
Chen Y, Zhang J, Li D et al (2016) Identification of a novel polo-like kinase 1 inhibitor that specifically blocks the functions of polo-box domain. Oncotarget 8:1234–1246
pmcid: 5352051
Syed N, Smith P, Sullivan A et al (2006) Transcriptional silencing of polo-like kinase 2 ( SNK / PLK2 ) is a frequent event in B-cell malignancies. Blood 107:250–256
pubmed: 16160013
Yang Y, Bai J, Shen R et al (2008) Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1?? Under hypoxic conditions. Cancer Res 68:4077–4085
pubmed: 18519666
pmcid: 3725591
Brożek J, Bryl E, Płoszyńska A et al (2009) P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 31:493–499
pubmed: 19564743
Dhooge C, De Moerloose B, Laureys G et al (1999) P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol 105:676–683
pubmed: 10354131
Wu CP, Hsieh CH, Hsiao SH et al (2015) Human ATP-binding cassette transporter ABCB1 confers resistance to Volasertib (BI 6727), a selective inhibitor of polo-like kinase 1. Mol Pharm 12:3885–3895
pubmed: 26412161
Ferrarotto R, Goonatilake R, Young Yoo S et al (2016) Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung Cancer. Clin Cancer Res 22:1674–1686
pubmed: 26597303
Mailand N, Bekker-Jensen S, Bartek J, Lukas J (2006) Destruction of Claspin by SCF
pubmed: 16885021
Elowe S, Hümmer S, Uldschmid A et al (2007) On BubR1 regulates the stability of kinetochore – microtubule interactions. Genes Dev 21:2205–2219
pubmed: 17785528
pmcid: 1950859
Peters U, Cherian J, Kim JH et al (2006) Probing cell-division phenotype space and polo-like kinase function using small molecules. Nat Chem Biol 2:618–626
pubmed: 17028580
Elia AEH (2003) Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 299(80):1228–1231
pubmed: 12595692